Targeting tumours with novel radiopharmaceuticals
European Pharmaceutical Review
OCTOBER 19, 2023
With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. His research lab focused on second generation targeted radiotherapeutics which became the core technology of Noria Therapeutics, a company he started in 2017. Internet] Jaafar-Thiel, L.
Let's personalize your content